Actelion Pharmaceuticals Ltd Technographics

Discover the latest software purchases and digital transformation initiatives being undertaken by Actelion Pharmaceuticals Ltd and its business and technology executives. Each quarter our research team identifies on-prem and cloud applications that are being used by the 2624 Actelion Pharmaceuticals Ltd employees from the public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources.

During our research, we have identified that Actelion Pharmaceuticals Ltd has purchased the following applications: Microsoft Azure Cloud Services for Application Hosting and Computing Services in 2018, New Relic APM for Application Performance Management in 2021, BSI CTMS for Clinical Trial Management in 2006 and the related IT decision-makers and key stakeholders.

Our database provides customer insight and contextual information on which enterprise applications and software systems Actelion Pharmaceuticals Ltd is running and its propensity to invest more and deepen its relationship with Microsoft , Amazon Web Services (AWS) , New Relic or identify new suppliers as part of their overall Digital and IT transformation projects to stay competitive, fend off threats from disruptive forces, or comply with internal mandates to improve overall enterprise efficiency.

We have been analyzing Actelion Pharmaceuticals Ltd revenues, which have grown to $2.49 billion in 2024, plus its IT budget and roadmap, cloud software purchases, aggregating massive amounts of data points that form the basis of our forecast assumptions for Actelion Pharmaceuticals Ltd intention to invest in emerging technologies such as AI, Machine Learning, IoT, Blockchain, Autonomous Database or in cloud-based ERP, HCM, CRM, EPM, Procurement or Treasury applications.